Peter Lim

1.3k citations

37 papers · 885 indexed · 2 hit papers · h-index 13

Impact in

Reproductive Medicine top 2%
- Ovarian cancer diagnosis and treatment
- Endometriosis Research and Treatment
Obstetrics and Gynecology top 2%
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments

Papers in ⓘ

Reproductive Medicine 19
- Ovarian cancer diagnosis and treatment 13
- Endometriosis Research and Treatment 6
Obstetrics and Gynecology 16
- Endometrial and Cervical Cancer Treatments 14
- Uterine Myomas and Treatments 13

Co-authors: E.Y. Kang (8 shared papers)Kathleen N. Moore (6 shared papers)Ana Oaknin (6 shared papers)Bradley J. Monk (6 shared papers)Domenica Lorusso (3 shared papers)Susana Banerjee (3 shared papers)Karl Tamussino (1 shared paper)Conleth G. Murphy (2 shared papers)
Journals: Journal of Clinical Oncology (7 papers)Gynecologic Oncology (5 papers)Best Practice & Research Clinical Obstetrics & Gynaecology (3 papers)Annals of Oncology (2 papers)Journal of Minimally Invasive Gynecology (2 papers)
Partner nations: United States Canada Spain

In The Last Decade

Peter Lim

31 papers receiving 859 citations

Hit Papers

align trajectories log scale

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer 2023 · 81 citations

Peers

Countries citing papers authored by Peter Lim

Since Specialization

Citations

This map shows the geographic impact of Peter Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Lim more than expected).

Fields of papers citing papers by Peter Lim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Lim. The network helps show where Peter Lim may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Lim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Lim Line = papers co-authored together Peter Lim links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I Annals of Oncology ·Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo, Ana Oaknin, Giovanni Scambia, Domenica Lorusso, Gottfried E. Konecny, Susana Banerjee, Conleth G. Murphy, János L. Tanyi, Hal W. Hirte, Jason Konner, Peter Lim, Monica Prasad-Hayes, Bradley J. Monk, Patricia Pautier, Jiao Wang, Anna Berkenblit, Ignace Vergote, Michael J. Birrer Hit paper breakdown →	2021	186
2	A comparative detail analysis of the learning curve and surgical outcome for robotic hysterectomy with lymphadenectomy versus laparoscopic hysterectomy with lymphadenectomy in treatment of endometrial cancer: A case-matched controlled study of the first one hundred twenty two patients Gynecologic Oncology ·Peter Lim, E.Y. Kang, Do Hwan Park	2010	132
3	Learning Curve and Surgical Outcome for Robotic-Assisted Hysterectomy with Lymphadenectomy: Case-Matched Controlled Comparison with Laparoscopy and Laparotomy for Treatment of Endometrial Cancer Journal of Minimally Invasive Gynecology ·Peter Lim, E.Y. Kang, Do Hwan Park	2010	83
4	Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer Gynecologic Oncology ·Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Kathleen N. Moore, David M. O’Malley Hit paper breakdown →	2023	81
5	Multicenter analysis comparing robotic, open, laparoscopic, and vaginal hysterectomies performed by high‐volume surgeons for benign indications International Journal of Gynecology & Obstetrics ·Peter Lim, John T. Crane, Eric J. English, R.W. Farnam, Devin M. Garza, Marc L. Winter, Jerry L. Rozeboom	2016	73
6	Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study Journal of Clinical Oncology ·Robert A. Burger, Mark F. Brady, Michael A. Bookman, Bradley J. Monk, Joan L. Walker, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Gini F. Fleming, Peter Lim, Stephen C. Rubin, Noriyuki Katsumata, Sharon X. Liang	2014	57
7	Gastrointestinal Surgery in Patients with Ovarian Cancer Gynecologic Oncology ·Karl Tamussino, Peter Lim, Maurice J. Webb, Raymond A. Lee, Timothy G. Lesnick	2001	55
8	Robotic assisted total pelvic exenteration: A case report Gynecologic Oncology ·Peter Lim	2009	38
9	FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) Annals of Oncology ·Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo, Ana Oaknin, Giovanni Scambia, Domenica Lorusso, Robin Farias‐Eisner, Susana Banerjee, Conleth G. Murphy, János L. Tanyi, Hal W. Hirte, Jason Konner, Peter Lim, Monica Prasad Hayes, Bradley J. Monk, S. Kim, Jiao Wang, Patricia Pautier, I. Vergote, Michael J. Birrer	2019	36
10	ROCC/GOG-3043: A randomized non-inferiority trial of robotic versus open radical hysterectomy for early-stage cervical cancer. Journal of Clinical Oncology ·Kristin Bixel, Mario M. Leitão, Dana M. Chase, Allison Quick, Peter Lim, Ramez N. Eskander, Walter H. Gotlieb, Salvatore Lococo, Martin A Martino, Colleen McCormick, Tashanna Myers, Krishnansu S. Tewari, Brian M. Slomovitz, Joan L. Walker, Larry J. Copeland, Bradley J. Monk, Leslie M. Randall	2022	21
11	Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. Journal of Clinical Oncology ·David M. O’Malley, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Patrick A. Zweidler‐McKay, Jiuzhou Wang, Brooke Esteves, Kathleen N. Moore, Lucy Gilbert	2021	18
12	Factors in the feasibility and safety of outpatient robotic-assisted hysterectomy for endometrial or cervical carcinoma Gynecologic Oncology ·Tyson Matern, E.Y. Kang, Peter Lim	2020	13
13	Robot-assisted total intracorporeal low anterior resection with primary anastomosis and radical dissection for treatment of stage IV endometriosis with bowel involvement: morbidity and its outcome Journal of Robotic Surgery ·Peter Lim, E.Y. Kang, Do Hwan Park	2011	13
14	Robotic surgery in gynecology Best Practice & Research Clinical Obstetrics & Gynaecology ·Hys Ngan, Peter Lim	2017	12
15	Robot-assisted gynaecological cancer surgery—complications and prevention Best Practice & Research Clinical Obstetrics & Gynaecology ·Ka Yu Tse, Hys Ngan, Peter Lim	2017	10
16	Comparative analysis of genitourinary function after type C1 robotic nerve-sparing radical hysterectomy versus type C2 robotic radical hysterectomy Surgical Oncology ·Jiheum Paek, E.Y. Kang, Peter Lim	2019	10
17	Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer Future Oncology ·David M. O’Malley, Tashanna Myers, Pauline Wimberger, Toon Van Gorp, Andrés Redondo, David Cibula, Shibani Nicum, Manuel Rodrigues, Floor Backes, Joyce N. Barlin, Sharyn N. Lewin, Peter Lim, Bhavana Pothuri, Elisabeth Diver, Susana Banerjee, Domenica Lorusso	2024	9
18	Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer. Journal of Clinical Oncology ·Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Jiuzhou Wang, Brooke Esteves, Patrick A. Zweidler‐McKay, Kathleen N. Moore, David M. O’Malley	2020	7
19	How to prepare the patient for robotic surgery: before and during the operation Best Practice & Research Clinical Obstetrics & Gynaecology ·Peter Lim, E.Y. Kang	2017	5
20	The early surgical period in robotic radical hysterectomy is related to the recurrence after surgery in stage IB cervical cancer International Journal of Medical Sciences ·Jiheum Paek, Peter Lim	2021	5

About Peter Lim

Peter Lim is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Surgery, Oncology and Urology, having authored 37 papers that have together received 885 indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (14 papers), Ovarian cancer diagnosis and treatment (13 papers), Uterine Myomas and Treatments (13 papers), Minimally Invasive Surgical Techniques (8 papers), Endometriosis Research and Treatment (6 papers), Intraperitoneal and Appendiceal Malignancies (5 papers), HER2/EGFR in Cancer Research (4 papers) and Surgical Simulation and Training (3 papers). The work is most often cited by research in Reproductive Medicine (438 citations), Obstetrics and Gynecology (364 citations), Oncology (341 citations), Surgery (339 citations) and Pathology and Forensic Medicine (95 citations). Peter Lim has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include E.Y. Kang, Kathleen N. Moore, Ana Oaknin, Bradley J. Monk, Domenica Lorusso, Susana Banerjee, Karl Tamussino, Conleth G. Murphy, Maurice J. Webb and Michael J. Birrer. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Best Practice & Research Clinical Obstetrics & Gynaecology, Annals of Oncology and Journal of Minimally Invasive Gynecology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact